Background. Treatment of patients with multidrug-resistant tuberculosis requires prolonged therapy, often involving long hospital stays. Despite intensive and costly therapy, cure rates are relatively low.
Multidrug-resistant (MDR) tuberculosis has been found in all areas of the world, with some areas having an alarming number of cases [1, 2] . Treatment of MDR tuberculosis requires the use of antituberculosis drugs that are less potent, more costly, and generally more toxic than drugs used to treat drug-susceptible tuberculosis and require prolonged administration for up to 2 or more years. Even under the best circumstances, treatment of MDR tuberculosis is associated with significant overall morbidity and mortality and substantial increase in cost [3] [4] [5] [6] [7] .
Most studies involving MDR tuberculosis have used an inpatient approach with prolonged hospital stays [8] [9] [10] [11] [12] [13] . The advantage of this approach is that patients can be assessed for drug-related adverse effects and adherence to treatment. In addition, respiratory isolation until the patient has negative results of tests of sputum smears is thought to prevent transmission of MDR organisms to others in the community. However, prolonged hospital stays account for a large proportion of the overall costs of treating patients with MDR tuberculosis [3, 5, 14, 15] . In addition, lengthy hospital stays can result in nosocomial transmission, thereby adding to the medical and financial burden of treating this disease. Most outbreaks of MDR tuberculosis have been reported in hospitals [16] [17] [18] .
Outpatient treatment of MDR tuberculosis may be perceived as problematic because of recommendations for daily supervision and, frequently, multiple daily doses of medications. Several reports of outpatientbased treatment of patients with MDR tuberculosis have demonstrated encouraging results [19] [20] [21] [22] . Here, we present the outcomes and costs of treatment of patients with MDR tuberculosis in San Francisco by use of a largely outpatient approach. In addition, we assessed the spread of MDR strains of Mycobacterium tuberculosis by means of genotyping techniques.
METHODS
We retrospectively reviewed the records for all patients infected with M. tuberculosis isolates resistant to at least isoniazid and rifampin reported to the Tuberculosis Section of the San Francisco Department of Public Health during the period of 1 January 1982 through 31 December 2000. The study was stopped in the year 2000 to provide у2 years of follow-up for patients who completed therapy. The Committee on Human Research at the University of California, San Francisco, approved the study.
All antituberculosis drugs taken by the patient, duration of treatment, and number of weeks of directly observed therapy (DOT) were recorded. DOT was provided in the field by unlicensed public health personnel or at the clinic by an assigned nurse. The ratio of patients receiving field-based versus clinicbased DOT was ∼1:3. Medications used in field-based DOT were individually prepackaged by clinic nurses before each visit. During the period of the study in which costs were calculated, the Tuberculosis Control Program used 4-5 registered nurses, 3-4 disease-control investigators, and ∼8 health care workers.
Culture conversion date was defined as the report date of the first negative culture result in a series of at least 3 consecutive negative culture results. Patients were considered to have responded to therapy if their culture results converted to negative and to have experienced treatment failure if culture results remained positive. A patient was considered cured on finishing a prescribed course of treatment with a combination of the drugs to which the isolate was susceptible (table 1) with a microbiological response and on demonstrating clinical evidence of resolution of symptoms. Relapse was defined as the reoccurrence of a positive culture result after having been considered cured. Patients were considered to have abandoned treatment if they stopped therapy before cure. Acquired MDR referred to the development of isoniazid and rifampin resistance in a strain that was initially susceptible to 1 or both of these drugs. Patients were monitored for signs of drug toxicity, and for the purposes of this study, adverse effects were characterized according to World Health Organization guidelines [23] . Follow-up assessments included clinical and microbiological evaluation at least 6, 12, and 24 months after completing therapy.
Smears for acid-fast bacilli (AFB), cultures for mycobacteria, and drug susceptibility testing were done in licensed laboratories by use of standard methods [24, 25] . Drug resistance results were confirmed by culture on solid media. Any patient found to be infected with an MDR strain had susceptibility testing repeated for both first-and second-line antituberculosis drugs. For isolates obtained from 1991 through 2000, IS6110-based restriction fragment-length polymorphism (RFLP) and polymorphic guanine cytosine rich sequence-based genotype analysis were done and analyzed by internationally standardized methods [26, 27] .
Cost data were calculated from the health services provided to 11 patients with MDR tuberculosis treated during the period of 1 January 1995 through 31 December 2000. Charge data were used as a proxy for costs. Outpatient charges were itemized by codes for allowable insurance services. The services provided were based on the American Medical Association's Current Procedural Terminology, 1999 codes, and the charges were based on the prevailing charges in San Francisco Bay Area public health and community hospitals. Charges for health services that were included were all visits to the tuberculosis clinic that required a physician or registered nurse encounter; visits in the field by the health care personnel; the local price of drugs; mode, dose, and frequency of administration; and whether the drugs were given by DOT. All laboratory, microbiological, and imaging studies were included in the cost analysis. Hospitalization charges for MDR tuberculosis were extrapolated from data published in a prospective study conducted by the Centers for Disease Control and Prevention in which the San Francisco tuberculosis program participated [28] .
Statistics were computed by use of SAS software, version 8.2 (SAS Institute). Continuous variables were compared with t tests or Wilcoxon exact tests, and categorical variables were compared by either x 2 test or Fisher's exact test [29] .
RESULTS

Demographic and disease characteristics.
A total of 5407 cases of tuberculosis were reported in San Francisco during the period of 1 January 1982 through 31 December 2000. Of the 4046 cases for which drug susceptibility results were available, 51 (1.3%) were identified as being due to MDR strains. Three cases were excluded from the study: 1 was determined by RFLP analysis to have been misidentified as the result of laboratory contamination; the other 2 were not treated in San Francisco. The 48 remaining cases constitute the study population. The 2 most common associated medical conditions observed in the cohort were HIV infection ( ), all with CD4 cell counts n p 11 of !121 cells/mL, (median CD4 cell count, 50 cells/mL; range, 0-120 cells/mL) and diabetes mellitus ( ). n p 5 Twelve patients (25%) were born in the United States, and 36 (75%) were foreign born. Thirty-one patients (65%) had a prior diagnosis of tuberculosis; 27 (87%) of these were foreignborn. The median time between any prior treatment and current diagnosis of MDR tuberculosis was 9 years (range, !1-30 years). Cavitary tuberculosis was present in 21 (47%) of 45 patients with pulmonary disease. Only 1 of the HIV-infected patients had cavitary tuberculosis. Thirty-one patients (65%) had AFB identified in the initial microscopic examination of sputum specimens. Susceptibility testing of the isolates showed resistance to a median of 3 drugs (range, 2-9 drugs). Thirty-six (75%) of 48 patients had MDR strains identified in the first culture result reported, and 12 (25%) had MDR strains develop during the initial course of treatment; 7 (58%) of these 12 patients were HIV seropositive. Of the 12 patients whose strains developed MDR, 6 had strains that were initially resistant to either isoniazid or rifampin alone and during therapy subsequently became MDR. Only 2 patients developed MDR after 1995, and both were HIV seropositive. The demographic, clinical, and microbiological characteristics of the 48 patients with MDR tuberculosis, together and stratified by HIV status, are summarized in table 2.
Treatment regimens. Isolates from 41 (85%) of 48 patients were initially susceptible to pyrazinamide and/or ethambutol. These patients received 1 or both agents in combination with other antituberculosis drugs during the course of therapy. The most common additional drugs given were aminoglycosides or polypeptides (96%), fluoroquinolones (69%), and cycloserine (60%). A mean of 5 second-line agents were used by both HIVseronegative and -seropositive patients (range, 3-12 agents and 2-10 agents, respectively) (table 3). Forty-two (88%) of 48 patients received DOT throughout their treatment for MDR tuberculosis, with the remaining 6 patients receiving partial DOT; for patients who received partial DOT, only the administration of parenteral drugs was observed directly. After 1994, all patients with MDR tuberculosis were treated with DOT.
Hospitalization and surgery. Twenty-one (44%) of 48 patients required hospitalization, with a median stay of 14 days (range, 3-74 days). Of the 21 hospitalized patients, 11 (52%) were HIV seropositive; all HIV-seropositive patients were hospitalized. The median durations of hospitalization were 21 days (range, 5-74 days) for HIV-seropositive patients and 10.5 days (range, 3-45 days) for HIV-seronegative patients. Three HIVseronegative patients with persistently positive culture results underwent surgical procedures: 2 had a modified Eloesser flap performed for drainage of a tuberculous empyema, and 1 had a left upper lobectomy. Results of sputum cultures for these 3 patients subsequently became negative, and all 3 patients were cured.
Adverse effects. Twenty-three (48%) of 48 patients reported no adverse effects, 8 (17%) had minor adverse effects, and 17 (35%) had more severe adverse effects: 13% had a toxic reaction, 9% had a hypersensitivity reaction, and 13% had an idiosyncratic reaction (table 1) . Severe adverse events occurred in 3 HIV-seropositive patients (27%) and 14 HIV-seronegative patients (38%). All 17 patients with severe side effects required discontinuation of at least 1 antituberculosis agent, and for 3 of these patients, hospitalization was necessary because of the reaction.
Outcomes of treatment.
Overall, 40 patients (83%) had conversion of sputum culture results to negative in response to the initial treatment regimen for MDR organisms. When stratified by HIV infection status, 34 (92%) of the 37 HIV-seronegative patients had conversion of culture results to negative, compared with only 6 (55%) of the 11 HIV-seropositive patients (  ; table 3 ). Four pa-P p .01 tients (all HIV seronegative) were excluded from the end-oftreatment outcome analysis because they were transferred to another tuberculosis-control jurisdiction ( ) or abann p 3 doned therapy ( ) before completion. Two of the 3 patients n p 1 who transferred had negative results of AFB smears and cultures 1 month after initiation of treatment and continued to have negative results of culture after 6 months of treatment. The patient who abandoned therapy had negative results of culture after 6 weeks of therapy.
The cure rates by HIV status for patients who completed treatment were 97% (32 of 33 patients) for HIV-seronegative patients and 9% (1 of 11) for HIV-seropositive patients. The 1 HIV-seronegative patient with treatment failure died of chronic MDR tuberculosis after 8 years of chemotherapy. This patient had a large cavity but was not a candidate for surgery because of his advanced age and overall poor medical condition. An additional HIV-seronegative patient who had been cured initially had relapse with the same strain of M. tuberculosis ∼5 years later. Of the 10 HIV-seropositive patients who died during ). The cost P p .04 for 1 HIV-seronegative patient whose isolate was resistant to 5 drugs was ∼$100,000; that patient received prolonged intravenous therapy with imipenem and amikacin.
Genotyping data. Thirty-three of 35 MDR tuberculosis cases between 1991 and 2000 had strain genotyping information available for analysis, of which 10 (30%) were clustered. None of these cases clustered with another MDR tuberculosis case; thus, no secondary cases of MDR tuberculosis were identified on the basis of genotyping and contact investigation (data not shown). Analysis of individual strains showed that 1 United States-born patient whose isolate had a unique genotype pattern in our database was hospitalized because of an HIV-related condition in a hospital in Argentina in January 1996. This patient's infecting isolate had the same resistance and genotype pattern as the strain that caused a nosocomial outbreak in the Nerin Hospital in Buenos Aires in 1996 [16] .
DISCUSSION
This study demonstrates that, within the context of an effective tuberculosis-control program [30] , it is feasible to treat MDR tuberculosis in HIV-seronegative patients with the use of appropriate intensive treatment regimens, largely with an outpatient approach, and achieve high cure rates comparable with those obtained for patients with drug-susceptible tuberculosis. The costs incurred, although still quite high, were much lower than has been described previously [3-5, 14, 15] . Among HIVseronegative patients, the overall cure rate was 97%, with only 1 patient experiencing relapse. In striking contrast, however, only 1 HIV-infected patient was cured, and this patient sub- sequently experienced relapse and died. In another cohort of patients with MDR tuberculosis treated on an outpatient basis, the probable cure rate was 83% (cure by HIV status was not reported) [21] , whereas treatment responses from 50% to 80% have been described in other reports of therapy with an inpatient approach [7] [8] [9] [10] [11] [12] [13] . In our cohort, most of our patients received DOT as outpatients, and fewer than one-half required hospitalization and only for a median stay of 2 weeks. Of note, no secondary cases of MDR tuberculosis were observed in known contacts or other members of the San Francisco community, a finding that we have reported previously [31] .
The differences between our experience and other reported outcomes of treatment for MDR tuberculosis are likely related to differences in patient populations with varying degrees of drug resistance, severity of lung involvement, and differences in treatment regimens [22] . For example, in the reports from Peru [21] and from the National Jewish Medical and Research Center [9] , patients had tuberculosis for a median of 6-8 years, with isolates that were resistant to an average of 6 drugs. In contrast, in San Francisco, MDR tuberculosis was recognized early, and patients had isolates that were resistant to a median of 3 drugs only. Therefore, we were able to use ethambutol and/or pyrazinamide to treat 85% of patients. Patients infected with strains susceptible to ethambutol and pyrazinamide tended to have a favorable outcome in the report from Peru [21] . In addition, ∼70% of our patients received a fluoroquinolone, which has also been associated with better treatment outcomes in patients with MDR tuberculosis [12] .
In a recent case series from National Jewish Medical and
Research Center, the overall cure rates were better for patients who had lung resection [12] . In our study, only 3 patients underwent surgical procedures, only 1 of which was a resection, after they did not respond to appropriate drug regimens. These patients had negative results of AFB smears and cultures shortly after surgery and were eventually cured. Prolonged hospitalization can result in nosocomial spread and greatly increases the overall cost of treating MDR tuberculosis. In this study, the only patient with documented proof of transmission of an MDR strain acquired the strain during an outbreak of MDR tuberculosis at a hospital in Argentina [17] . Previous studies have estimated that the costs of MDR tuberculosis range from $60,000 to $180,000 [3, 5, 15] . These studies have included prolonged hospital stays that greatly increased the cost of care. In a recent study published by the Centers for Disease Control and Prevention that reported both direct and indirect costs, the average inpatient and outpatient costs of treating a patient with MDR tuberculosis were $25,853 and $19,028 per person, respectively [14] . The estimated combined inpatient and outpatient median cost of therapy for patients with MDR tuberculosis in our cohort was $27,752 per patient (table 4) . During the same period, the cost of treating ambulatory patients with tuberculosis caused by susceptible organisms with use of DOT was $7193, and without DOT, it was $3557. Thus, the overall short durations of hospitalization for patients with MDR tuberculosis in San Francisco resulted in the reduced cost of treatment. With this strategy, we did not observe any nosocomial or community transmission of MDR tuberculosis [31] .
A limitation of our study is that charges were used to estimate the costs of treatment for MDR tuberculosis. Although our cost estimates are lower than published treatment costs [3, 5, 15] , we likely overestimated the actual expense of the services provided [14, 32] because we used charges as a proxy to estimate cost. Our outpatient-based treatment experience and the experience in Peru [6] make a strong case for moving treatment of MDR tuberculosis to the outpatient setting, at least among HIV-seronegative patients infected with isolates that are resistant to only a few drugs.
Compared with the excellent treatment outcomes among HIV-seronegative patients, HIV-seropositive patients with MDR tuberculosis had very poor outcomes, as has been described elsewhere [33] [34] [35] . In this study, all HIV-seropositive patients were severely immunocompromised, and of the 54.6% who achieved conversion of culture results, none survived. All HIV-seropositive patients died either during treatment or during follow-up, and the deaths were often caused by other HIVassociated conditions. Only 2 patients received combination antiretroviral treatment during therapy for their MDR disease. Although there are no data to substantiate benefit, the prolonged time to conversion of culture results and the high mortality rate suggest that combination antiretroviral treatment should be initiated promptly in patients with HIV infection and MDR tuberculosis. In addition, because of the high frequency of acquired drug resistance in HIV-seropositive persons, even with DOT, measurement of serum drug concentrations in advanced HIV disease [36, 37] should be strongly considered.
In summary, our results demonstrate that it is feasible to treat MDR tuberculosis among HIV-seronegative patients with the use of appropriate intensive treatment regimes and an outpatient-based approach and less costly than conventional treatment. With this approach, we did not observe any secondary cases of MDR tuberculosis. It is important to note that San Francisco is a relatively small urban area that has availability of MDR treatment expertise and resources focused on outpatient case management that may not be available in other programs. However, given the cost savings of outpatient management over hospitalization, it may be possible to redirect resources so that an effective outpatient management strategy can be developed. In settings that can ensure completion of treatment through DOT and have available resources for second-line drugs with an infrastructure for careful monitoring, an outpatient approach for treatment of MDR tuberculosis should be considered.
